Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients.

Massa C, Robins H, Desmarais C, Riemann D, Fahldieck C, Fornara P, Seliger B.

Oncotarget. 2017 Mar 28;8(13):21212-21228. doi: 10.18632/oncotarget.15064.

2.

Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.

Flörcken A, Kopp J, van Lessen A, Movassaghi K, Takvorian A, Jöhrens K, Möbs M, Schönemann C, Sawitzki B, Egerer K, Dörken B, Pezzutto A, Westermann J.

Hum Vaccin Immunother. 2013 Jun;9(6):1217-27. doi: 10.4161/hv.24149. Epub 2013 Mar 4.

3.

High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.

Pohla H, Buchner A, Stadlbauer B, Frankenberger B, Stevanovic S, Walter S, Frank R, Schwachula T, Olek S, Kopp J, Willimsky G, Stief CG, Hofstetter A, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ.

Mol Med. 2013 Feb 8;18:1499-508. doi: 10.2119/molmed.2012.00221.

4.

Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm.

Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ, Quinn DI.

Mol Cancer Ther. 2012 Mar;11(3):526-37. doi: 10.1158/1535-7163.MCT-11-0806. Epub 2012 Feb 17. Review.

5.

Immunotherapy for renal cell carcinoma.

Itsumi M, Tatsugami K.

Clin Dev Immunol. 2010;2010:284581. doi: 10.1155/2010/284581. Epub 2011 Jan 3.

6.

Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.

Liu C, Russell SJ, Peng KW.

Mol Ther. 2010 Jun;18(6):1155-64. doi: 10.1038/mt.2010.43. Epub 2010 Mar 16.

Supplemental Content

Support Center